18 November 2025 | Tuesday | News
Halda Therapeutics announced that it has entered into a definitive agreement pursuant to which Johnson & Johnson will acquire Halda for $3.05 billion, payable in cash at closing, subject to customary adjustments.
Halda’s portfolio includes HLD-0915, a first-in-class, oral RIPTAC™ therapeutic, in development for metastatic castration-resistant prostate cancer (mCRPC). Recently presented Phase 1/2 data demonstrated this novel therapy was well-tolerated and showed encouraging signs of anti-tumor activity, including reductions in prostate-specific antigen (PSA) and responses by Response Evaluation Criteria in Solid Tumors (RECIST), in patients with advanced prostate cancer, many of whom had progressed after multiple prior therapies and exhausted available treatments.
“Halda is dedicated to advancing its novel RIPTAC modality to develop the next generation of selective, proximity-based small molecule therapeutics for patients with serious diseases,” said Christian S. Schade, President and CEO of Halda. “Through this transaction, we will continue to rapidly develop this promising program for patients with prostate cancer and advance Halda’s innovative pipeline from its RIPTAC™ platform to address a range of diseases. This announcement is a tribute to the years of scientific effort to develop this novel, first-in-class modality and deliver significant value to our shareholders.”
The transaction is expected to close within the next few months, subject to the satisfaction of customary closing conditions, including expiration of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976. Until then, Johnson & Johnson and Halda will continue to operate as separate and independent companies.
Centerview Partners LLC is acting as exclusive financial advisor to Halda and Goodwin Procter is serving as legal counsel.
© 2025 Biopharma Boardroom. All Rights Reserved.
